Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 1.10
CELG's Cash to Debt is ranked higher than
57% of the 1270 Companies
in the Global Biotechnology industry.

( Industry Median: 60.65 vs. CELG: 1.10 )
CELG' s 10-Year Cash to Debt Range
Min: 0.06   Max: No Debt
Current: 1.1

Equity to Asset 0.38
CELG's Equity to Asset is ranked higher than
57% of the 968 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. CELG: 0.38 )
CELG' s 10-Year Equity to Asset Range
Min: -0.3   Max: 0.88
Current: 0.38

-0.3
0.88
Interest Coverage 14.30
CELG's Interest Coverage is ranked higher than
55% of the 575 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CELG: 14.30 )
CELG' s 10-Year Interest Coverage Range
Min: 4.47   Max: 428.04
Current: 14.3

4.47
428.04
F-Score: 8
Z-Score: 7.26
M-Score: -2.59
WACC vs ROIC
15.10%
41.19%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 32.84
CELG's Operating margin (%) is ranked higher than
96% of the 1045 Companies
in the Global Biotechnology industry.

( Industry Median: -75.73 vs. CELG: 32.84 )
CELG' s 10-Year Operating margin (%) Range
Min: -2309.09   Max: 32.84
Current: 32.84

-2309.09
32.84
Net-margin (%) 26.07
CELG's Net-margin (%) is ranked higher than
95% of the 1045 Companies
in the Global Biotechnology industry.

( Industry Median: -78.17 vs. CELG: 26.07 )
CELG' s 10-Year Net-margin (%) Range
Min: -2309.09   Max: 28.88
Current: 26.07

-2309.09
28.88
ROE (%) 36.74
CELG's ROE (%) is ranked higher than
98% of the 1154 Companies
in the Global Biotechnology industry.

( Industry Median: -34.19 vs. CELG: 36.74 )
CELG' s 10-Year ROE (%) Range
Min: -425.42   Max: 33.02
Current: 36.74

-425.42
33.02
ROA (%) 13.26
CELG's ROA (%) is ranked higher than
96% of the 1274 Companies
in the Global Biotechnology industry.

( Industry Median: -27.54 vs. CELG: 13.26 )
CELG' s 10-Year ROA (%) Range
Min: -166.78   Max: 15.8
Current: 13.26

-166.78
15.8
ROC (Joel Greenblatt) (%) 219.73
CELG's ROC (Joel Greenblatt) (%) is ranked higher than
98% of the 1243 Companies
in the Global Biotechnology industry.

( Industry Median: -394.00 vs. CELG: 219.73 )
CELG' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1378.72   Max: 213.62
Current: 219.73

-1378.72
213.62
Revenue Growth (3Y)(%) 20.60
CELG's Revenue Growth (3Y)(%) is ranked higher than
91% of the 708 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. CELG: 20.60 )
CELG' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 166.8
Current: 20.6

0
166.8
EBITDA Growth (3Y)(%) 20.40
CELG's EBITDA Growth (3Y)(%) is ranked higher than
90% of the 697 Companies
in the Global Biotechnology industry.

( Industry Median: -4.50 vs. CELG: 20.40 )
CELG' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 75.6
Current: 20.4

0
75.6
EPS Growth (3Y)(%) 19.00
CELG's EPS Growth (3Y)(%) is ranked higher than
90% of the 699 Companies
in the Global Biotechnology industry.

( Industry Median: -6.70 vs. CELG: 19.00 )
CELG' s 10-Year EPS Growth (3Y)(%) Range
Min: -63.2   Max: 118.1
Current: 19

-63.2
118.1
» CELG's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

CELG Guru Trades in Q1 2014

John Burbank 1,670 sh (New)
Ken Fisher 37,321 sh (+1591.8%)
Ray Dalio 71,200 sh (+962.69%)
Louis Moore Bacon 42,614 sh (+752.28%)
Steven Cohen 71,089 sh (+276.79%)
Paul Tudor Jones 6,686 sh (+178.35%)
Jim Simons 1,606,830 sh (+14.33%)
Ronald Muhlenkamp 149,325 sh (+1.29%)
Pioneer Investments 1,552,050 sh (+0.95%)
John Keeley Sold Out
Mario Gabelli 10,770 sh (-3.58%)
RS Investment Management 40,572 sh (-4.15%)
Chuck Royce 600 sh (-33.33%)
Jeremy Grantham 34,100 sh (-60.77%)
» More
Q2 2014

CELG Guru Trades in Q2 2014

George Soros 688,000 sh (New)
Joel Greenblatt 63,980 sh (New)
Stanley Druckenmiller 276,000 sh (New)
Ken Fisher 131,064 sh (+75.59%)
Mario Gabelli 23,120 sh (+7.34%)
Steven Cohen 204,200 sh (unchged)
Paul Tudor Jones Sold Out
Louis Moore Bacon Sold Out
John Burbank Sold Out
Ray Dalio Sold Out
Chuck Royce Sold Out
Pioneer Investments 3,052,643 sh (-1.66%)
RS Investment Management 75,104 sh (-7.44%)
Jeremy Grantham 50,000 sh (-26.69%)
Ronald Muhlenkamp 144,140 sh (-51.74%)
Jim Simons 495,900 sh (-84.57%)
» More
Q3 2014

CELG Guru Trades in Q3 2014

Louis Moore Bacon 55,000 sh (New)
John Hussman 25,000 sh (New)
Stanley Druckenmiller 560,600 sh (+103.12%)
Ken Fisher 232,137 sh (+77.12%)
RS Investment Management 86,904 sh (+15.71%)
Mario Gabelli 25,760 sh (+11.42%)
Ronald Muhlenkamp 146,940 sh (+1.94%)
Pioneer Investments 3,080,374 sh (unchged)
Joel Greenblatt Sold Out
George Soros Sold Out
Steven Cohen Sold Out
Jeremy Grantham Sold Out
Jim Simons 30,400 sh (-93.87%)
» More
Q4 2014

CELG Guru Trades in Q4 2014

Joel Greenblatt 10,259 sh (New)
Steven Cohen 110,400 sh (New)
Paul Tudor Jones 3,776 sh (New)
Pioneer Investments 3,376,570 sh (+9.62%)
John Hussman Sold Out
Louis Moore Bacon Sold Out
Jim Simons Sold Out
Ken Fisher 227,331 sh (-2.07%)
Mario Gabelli 24,960 sh (-3.11%)
RS Investment Management 76,482 sh (-11.99%)
Stanley Druckenmiller 434,100 sh (-22.57%)
Ronald Muhlenkamp 86,240 sh (-41.31%)
» More
» Details

Insider Trades

Latest Guru Trades with CELG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ronald Muhlenkamp 2014-12-31 Reduce -41.31%1.03%$86.38 - $118.68 $ 123.117%86240
John Hussman 2014-12-31 Sold Out 0.2%$86.38 - $118.68 $ 123.117%0
Joel Greenblatt 2014-12-31 New Buy0.01%$86.38 - $118.68 $ 123.116%10259
George Soros 2014-09-30 Sold Out 0.45%$83.13 - $96.21 $ 123.136%0
John Hussman 2014-09-30 New Buy0.2%$83.13 - $96.21 $ 123.136%25000
Joel Greenblatt 2014-09-30 Sold Out 0.07%$83.13 - $96.21 $ 123.136%0
Ken Fisher 2014-09-30 Add 77.12%0.02%$83.13 - $96.21 $ 123.136%232137
Ronald Muhlenkamp 2014-06-30 Reduce -51.74%1.91%$68.45 - $86.8 $ 123.162%144140
George Soros 2014-06-30 New Buy0.45%$68.45 - $86.8 $ 123.162%688000
Ray Dalio 2014-06-30 Sold Out 0.08%$68.45 - $86.8 $ 123.162%0
Joel Greenblatt 2014-06-30 New Buy0.07%$68.45 - $86.8 $ 123.162%63980
Ken Fisher 2014-06-30 Add 75.59%0.01%$68.45 - $86.8 $ 123.162%131064
John Burbank 2014-06-30 Sold Out 0.01%$68.45 - $86.8 $ 123.162%0
Ray Dalio 2014-03-31 Add 962.69%0.07%$69.65 - $85.97 $ 123.155%142400
John Burbank 2014-03-31 New Buy0.01%$69.65 - $85.97 $ 123.155%3340
Ken Fisher 2014-03-31 Add 1591.8%0.01%$69.65 - $85.97 $ 123.155%74642
John Keeley 2014-03-31 Sold Out $69.65 - $85.97 $ 123.155%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 51.40
CELG's P/E(ttm) is ranked higher than
91% of the 1354 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CELG: 51.40 )
CELG' s 10-Year P/E(ttm) Range
Min: 17.91   Max: 618.59
Current: 51.4

17.91
618.59
Forward P/E 19.12
CELG's Forward P/E is ranked higher than
96% of the 1354 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CELG: 19.12 )
N/A
PE(NRI) 51.30
CELG's PE(NRI) is ranked higher than
91% of the 1354 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CELG: 51.30 )
CELG' s 10-Year PE(NRI) Range
Min: 17.81   Max: 482.5
Current: 51.3

17.81
482.5
P/B 15.07
CELG's P/B is ranked higher than
58% of the 1354 Companies
in the Global Biotechnology industry.

( Industry Median: 6.64 vs. CELG: 15.07 )
CELG' s 10-Year P/B Range
Min: 4.02   Max: 23.45
Current: 15.07

4.02
23.45
P/S 13.42
CELG's P/S is ranked higher than
79% of the 1354 Companies
in the Global Biotechnology industry.

( Industry Median: 30.34 vs. CELG: 13.42 )
CELG' s 10-Year P/S Range
Min: 5.37   Max: 28.35
Current: 13.42

5.37
28.35
PFCF 39.08
CELG's PFCF is ranked higher than
94% of the 1354 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CELG: 39.08 )
CELG' s 10-Year PFCF Range
Min: 14.96   Max: 99999999.99
Current: 39.08

14.96
99999999.99
POCF 36.64
CELG's POCF is ranked higher than
92% of the 1354 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CELG: 36.64 )
CELG' s 10-Year POCF Range
Min: 13.82   Max: 937.83
Current: 36.64

13.82
937.83
EV-to-EBIT 37.56
CELG's EV-to-EBIT is ranked higher than
91% of the 1354 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CELG: 37.56 )
CELG' s 10-Year EV-to-EBIT Range
Min: -26.2   Max: 820.6
Current: 37.56

-26.2
820.6
PEG 2.23
CELG's PEG is ranked higher than
97% of the 1354 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CELG: 2.23 )
CELG' s 10-Year PEG Range
Min: 1.38   Max: 2.92
Current: 2.23

1.38
2.92
Shiller P/E 81.07
CELG's Shiller P/E is ranked higher than
95% of the 1354 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CELG: 81.07 )
CELG' s 10-Year Shiller P/E Range
Min: 56.57   Max: 2211
Current: 81.07

56.57
2211
Current Ratio 4.60
CELG's Current Ratio is ranked higher than
80% of the 1262 Companies
in the Global Biotechnology industry.

( Industry Median: 4.61 vs. CELG: 4.60 )
CELG' s 10-Year Current Ratio Range
Min: 1.35   Max: 11.23
Current: 4.6

1.35
11.23
Quick Ratio 4.41
CELG's Quick Ratio is ranked higher than
80% of the 1262 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. CELG: 4.41 )
CELG' s 10-Year Quick Ratio Range
Min: 1.13   Max: 11.11
Current: 4.41

1.13
11.11
Days Inventory 343.02
CELG's Days Inventory is ranked higher than
79% of the 1354 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CELG: 343.02 )
CELG' s 10-Year Days Inventory Range
Min: 49.98   Max: 584
Current: 343.02

49.98
584
Days Sales Outstanding 55.52
CELG's Days Sales Outstanding is ranked higher than
86% of the 1354 Companies
in the Global Biotechnology industry.

( Industry Median: 116.17 vs. CELG: 55.52 )
CELG' s 10-Year Days Sales Outstanding Range
Min: 42.33   Max: 464.55
Current: 55.52

42.33
464.55

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 373.03
CELG's Price/Tangible Book is ranked lower than
55% of the 1354 Companies
in the Global Biotechnology industry.

( Industry Median: 10.00 vs. CELG: 373.03 )
CELG' s 10-Year Price/Tangible Book Range
Min: 6.24   Max: 338.97
Current: 373.03

6.24
338.97
Price/DCF (Projected) 3.39
CELG's Price/DCF (Projected) is ranked higher than
95% of the 1354 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CELG: 3.39 )
CELG' s 10-Year Price/DCF (Projected) Range
Min: 1.77   Max: 40.07
Current: 3.39

1.77
40.07
Price/Median PS Value 1.23
CELG's Price/Median PS Value is ranked higher than
81% of the 1354 Companies
in the Global Biotechnology industry.

( Industry Median: 2.49 vs. CELG: 1.23 )
CELG' s 10-Year Price/Median PS Value Range
Min: 0.58   Max: 6.63
Current: 1.23

0.58
6.63
Price/Peter Lynch Fair Value 2.50
CELG's Price/Peter Lynch Fair Value is ranked higher than
98% of the 1354 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CELG: 2.50 )
CELG' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.46   Max: 5.1
Current: 2.5

0.46
5.1
Price/Graham Number 28.43
CELG's Price/Graham Number is ranked lower than
51% of the 1354 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CELG: 28.43 )
CELG' s 10-Year Price/Graham Number Range
Min: 3.29   Max: 25.83
Current: 28.43

3.29
25.83
Earnings Yield (Greenblatt) 2.70
CELG's Earnings Yield (Greenblatt) is ranked higher than
91% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. CELG: 2.70 )
CELG' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 6.6
Current: 2.7

0.1
6.6
Forward Rate of Return (Yacktman) 22.29
CELG's Forward Rate of Return (Yacktman) is ranked higher than
86% of the 167 Companies
in the Global Biotechnology industry.

( Industry Median: 15.69 vs. CELG: 22.29 )
CELG' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -0.5   Max: 34.8
Current: 22.29

-0.5
34.8

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CMXHY » details
Traded in other countries:CG3.Germany, CELG.Mexico, CELG.Switzerland,
Celgene Corp is incorporated in Delaware. The Company is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of new therapies designed to treat cancer and immune-inflammatory related diseases. The Company is engaged in new research and development designed to bring new therapies to market and we are involved in research in several scientific areas that may deliver proprietary next-generation therapies, targeting areas including intracellular signaling pathways, protein homeostasis and epigenetics in cancer and immune cells, immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies. The Company' commercial stage products include REVLIMID(r), VIDAZA(r), ABRAXANE(r), POMALYST(r)/IMNOVID(r), THALOMID(r) (inclusive of Thalidomide CelgeneTM), ISTODAX(r) and azacitidine for injection (generic version of VIDAZA(r)). The Company faces competition from Amgen, AstraZeneca, Bristol-Myers-Squibb, Eisai, Gilead, Johnson & Johnson, Novartis, Pharmacyclics, Roche/Genentech, Sanofi and Takeda, AbbVie, Amgen, Biogen Idec, Eisai, Johnson & Johnson, Merck, Pfizer and UCB S.A. Regulation by governmental authorities in the United States and other countries is a significant factor in the manufacture and marketing of pharmaceuticals and in its ongoing research and development activities.
» More Articles for CELG

Headlines

Articles On GuruFocus.com
February Pick Of Biotech Stocks Feb 17 2015 
Celleration Acquisition Just the Start of Alliqua’s M&A Strategy Feb 04 2015 
J.P. Morgan Chimes In With Ratings On BioTech Stocks Jan 06 2015 
UPDATE: Bionor Pharma Announces That the Combination of Vacc-4x + Revlimid(R) Is Well Tolerated and Nov 18 2014 
Bionor Pharma Announces That the Combination of Vacc-4x + Revlimid(R) Is Safe and Increases CD4 Coun Nov 17 2014 
Three Attractively Priced Small Cap Biotech Stocks Nov 05 2014 
Weekly 52-Week Highs Highlight: ALL, SRE, CLX, CELG Oct 05 2014 
Ken Fisher's Top Increases of the First Quarter Apr 22 2014 
David Winters' 2013 Letter to Wintergreen Fund Shareholders Mar 05 2014 
You Can No Longer Ignore Biotech Feb 07 2014 


More From Other Websites
Medivation Tops Q4 Views On Strong Xtandi Results Feb 26 2015
Celgene Encourages Psoriatic Arthritis Patients to “pSAY YES!” a Different Approach to Disease... Feb 25 2015
Psoriatic Arthritis Patients "pSAY YES!" to a Different Approach to Disease Management Feb 25 2015
Brain-Altering Devices May Supplant Drugs -- And Pharma Is OK With That Feb 24 2015
In The Book Of Life, A Second Map Is Established Feb 24 2015
United Therapeutics Blood Pressure Drug Lifts Q4 Feb 24 2015
ABRAXANE® Now Reimbursed in Italy as a First-Line Treatment of Adult Patients with Metastatic... Feb 24 2015
ABRAXANE® Now Reimbursed in Italy as a First-Line Treatment of Adult Patients with Metastatic... Feb 24 2015
[video]'Mad Money' Lightning Round: Buy Enbridge Energy Partners Feb 24 2015
Gilead Sciences, Inc., Amgen, Inc., Biogen Idec Inc Among Billionaires’ 5 Hottest Biotech Picks Feb 23 2015
Lightning Round: Don't listen to this CEO Feb 23 2015
Celgene Gains on Label Expansion of Revlimid in the EU - Analyst Blog Feb 23 2015
Blowing bubbles or smoke: Cramer's take on Nasdaq Feb 23 2015
Monday's Market Recap Feb 23 2015
Nasdaq: Why this time is different Feb 23 2015
6 Ways to Trade Celgene this Week Feb 23 2015
ADDING MULTIMEDIA REVLIMID® (Lenalidomide) Approved by the European Commission for the Treatment of... Feb 23 2015
10-K for Celgene Corp. Feb 22 2015
Celgene (CELG) Stock Gained Today on European Commission Approval of Revlimid Feb 20 2015
Celgene Up on Hematology Drug Revlimid's Label Expansion - Analyst Blog Feb 20 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK